12 active trials 7 recruiting 7 disease areas
| Early Phase 1 | 6 | |
| Phase 1 | 3 | |
| Phase 2 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2 | ||||
| NCT07188610 | PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic… | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | Recruiting | 2026-07-06 |
| Phase 1 | ||||
| NCT07284927 | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid… | Non-Hodgkin Lymphoma | Recruiting | 2025-12-16 |
| NCT05562024 | TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory… | B7-H3-positive Relapsed/ Refractory Neuroblastoma | Recruiting | 2023-02-27 |
| NCT07623681 | Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in… | CD7+ T-ALL/LBL | Not Yet Recruiting | 2026-06-03 |
| Early Phase 1 | ||||
| NCT07338604 | Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic… | Hematolymphoid Malignancies | Recruiting | 2026-01-14 |
| NCT07312630 | Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive… | Non-Hodgkin Lymphoma (NHL) | Recruiting | 2025-12-31 |
| NCT06092047 | UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. | CD19-positive Relapsed or Refractory B-cell Malignancies | Recruiting | 2025-05-16 |
| NCT06982534 | Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection. | Systemic Sclerosis (SSc) | Not Yet Recruiting | 2025-05-21 |
| NCT06982547 | Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection | Rheumatoid Arthritis (RA) | Not Yet Recruiting | 2025-05-21 |
| NCT06970951 | Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory… | Systemic Lupus Erythematosus | Not Yet Recruiting | 2025-05-14 |
| Not applicable | ||||
| NCT06279026 | UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | Recruiting | 2024-02-26 |
| NCT06871644 | Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases | Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria | Not Yet Recruiting | 2025-03-12 |
Acute Lymphoblastic Leukemia (ALL) (4) · Leukemia (3) · Scleroderma (3) · Non-Hodgkin Lymphoma (2) · Rheumatoid Arthritis (2) · Lupus (SLE) (1) · Multiple Myeloma (1)